A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

🏆 Top 20📊 OpenAlex

Most Cited Paper

in Estrogen and related hormone effects

18 Months Post-Publication

Class of 2026

“A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results”

AuthorsE Hamilton et al.

Richard D. Baird

JournalAnnals of Oncology

Sarah Cannon Research Institute

Citations29

DOI10.1016/j.annonc.2024.04.012

A research intelligence initiative by Pepkio

pri.pepkio.com

Topics

Camizestrant · selective estrogen receptor degrader · estrogen receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · phase I trial · dose escalation · dose expansion · SERENA-1 · Estrogen monotherapy · selective estrogen receptor degrader · selective estrogen receptor degrader

Share on X

Cite this ranking

Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31.

Methodology
Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459